Changes

|Yes

|Yes

|Yes

|Yes

|Yes

|Yes (although not established as a therapeutic marker, it associated with poor response to conventional chemotherapy)

|These genetic abnormalities serve as diagnostic markers and generally indicate an aggressive disease. This is due to their role in overexpressing oncogenes like ''TCL1A''. '''Major diagnostic criteria'''.<ref name=":6" />

|These genetic abnormalities serve as diagnostic markers and generally indicate an aggressive disease. This is due to their role in overexpressing oncogenes like ''TCL1A''. '''Major diagnostic criteria'''.<ref name=":6" />

|-

|-

|Yes

|Yes

|No

|No

|Yes

|Yes (although not established as a therapeutic marker, it associated with poor response to conventional chemotherapy)

|'''Major diagnostic criteria'''.<ref name=":6" />

|'''Major diagnostic criteria'''.<ref name=":6" />

|}

|}

|-

|-

|17

|17

|Abnormality

|Loss

|17p, 17q

|17p

|17p13

|17p13

|No

|No

|Yes

|Yes

|Yes (resistance to therapy)

|Yes (resistance to therapy)

|The TP53 gene is deleted (at 17p13.1), with overexpression of p53, in some cases. <ref name=":7" />

|May include TP53 gene at 17p13.1. <ref name=":7" />

|-

|-

|22

|22

**Involvement of specific sites (spleen, effusions)

**Involvement of specific sites (spleen, effusions)

== Characteristic Chromosomal Patterns ==

==Characteristic Chromosomal Patterns==

[[File:Inv(14)(q11.2q32).png|thumb|Inv(14)(q11.2q32)]]

[[File:Inv(14)(q11.2q32).png|thumb|Inv(14)(q11.2q32)]]

The most common chromosomal abnormality in T-PLL involves an inversion of chromosome 14, with breakpoints at q11.2 and q32.1, observed in about 60-80% of patients and described as inv(14). Additionally, in 10-20% of cases, there is a translocation t(14;14)(q11.2;q32.1).<ref name=":5" /> <ref name=":7" />

The most common chromosomal abnormality in T-PLL involves an inversion of chromosome 14, with breakpoints at q11.2 and q32.1, observed in about 60-80% of patients and described as inv(14). Additionally, in 10-20% of cases, there is a translocation t(14;14)(q11.2;q32.1).<ref name=":5" /> <ref name=":7" />

|Yes

|Yes

|Associated with resistance to therapy

|Associated with resistance to therapy

|Mutations in TP53 are less frequent than deletions.<ref name=":9" />

|Mutations in TP53 are less frequent than deletions.<ref name=":9" />May show overexpression of p53 in some cases.<ref name=":7" />

|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

|}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

==Epigenomic Alterations==

==Epigenomic Alterations==